XRAY vs. NVST, IONS, IBRX, ACHC, GKOS, APLS, EXEL, OPCH, LNTH, and OGN
Should you be buying DENTSPLY SIRONA stock or one of its competitors? The main competitors of DENTSPLY SIRONA include Envista (NVST), Ionis Pharmaceuticals (IONS), ImmunityBio (IBRX), Acadia Healthcare (ACHC), Glaukos (GKOS), Apellis Pharmaceuticals (APLS), Exelixis (EXEL), Option Care Health (OPCH), Lantheus (LNTH), and Organon & Co. (OGN). These companies are all part of the "medical" sector.
DENTSPLY SIRONA (NASDAQ:XRAY) and Envista (NYSE:NVST) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment, valuation and community ranking.
DENTSPLY SIRONA has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Envista has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500.
In the previous week, DENTSPLY SIRONA had 2 more articles in the media than Envista. MarketBeat recorded 7 mentions for DENTSPLY SIRONA and 5 mentions for Envista. DENTSPLY SIRONA's average media sentiment score of 1.16 beat Envista's score of 0.91 indicating that DENTSPLY SIRONA is being referred to more favorably in the media.
DENTSPLY SIRONA received 428 more outperform votes than Envista when rated by MarketBeat users. Likewise, 61.21% of users gave DENTSPLY SIRONA an outperform vote while only 39.44% of users gave Envista an outperform vote.
95.7% of DENTSPLY SIRONA shares are owned by institutional investors. 0.5% of DENTSPLY SIRONA shares are owned by insiders. Comparatively, 1.3% of Envista shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
DENTSPLY SIRONA has a net margin of -2.41% compared to Envista's net margin of -4.70%. DENTSPLY SIRONA's return on equity of 11.54% beat Envista's return on equity.
Envista has lower revenue, but higher earnings than DENTSPLY SIRONA. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.
DENTSPLY SIRONA presently has a consensus target price of $35.22, suggesting a potential upside of 24.11%. Envista has a consensus target price of $25.86, suggesting a potential upside of 35.20%. Given Envista's higher probable upside, analysts plainly believe Envista is more favorable than DENTSPLY SIRONA.
Summary
DENTSPLY SIRONA beats Envista on 13 of the 18 factors compared between the two stocks.
Get DENTSPLY SIRONA News Delivered to You Automatically
Sign up to receive the latest news and ratings for XRAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XRAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DENTSPLY SIRONA Competitors List
Related Companies and Tools
